Navigation Links
Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
Date:10/5/2010

in injections.
  • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN.

  • ADVERSE REACTIONS

    • Cervical Dystonia:  The most commonly observed adverse reactions (incidence greater than or equal to 10% of patients and twice the rate of placebo) for XEOMIN 120 Units and XEOMIN 240 Units, respectively, were: dysphagia (13%, 18%), neck pain (7%, 15%), muscle weakness (7%, 11%), and musculoskeletal pain (7%, 4%).
    • Blepharospasm: The most common adverse reactions (incidence greater than or equal to 10% of patients and twice the rate of placebo) for XEOMIN were eyelid ptosis (19%), dry mouth (16%), visual impairment (12%), diarrhea (8%), and headache (7%).

    DRUG INTERACTIONS

    Concomitant treatment of XEOMIN and aminoglycoside antibiotics, spectinomycin, or other agents that interfere with neuromuscular transmission (e.g., tubocurarine-like agents), or muscle relaxants, should be observed closely because the effect of XEOMIN may be potentiated.

    USE IN PREGNANCY

    Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Please see full prescribing information for XEOMIN, including Boxed WARNING, available at www.XEOMIN.com.

    About Merz

    Merz Pharmaceuticals, LLC is a part of the Merz Group of companies and was established in 1995 to develop and commercializ
    '/>"/>

    SOURCE Merz Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
    2. Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results
    3. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
    4. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
    5. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
    6. Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune Systems Ability to Destroy Anthrax Bacteria
    7. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
    8. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
    9. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
    10. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
    11. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... , July 30, ... Guidance   ... including Core Earnings and ... Highlights of Q1 results  ... Underlying core earnings and underlying core EPS were flat, year-to-year , ...
    (Date:7/29/2015)... Pa. , July 29, 2015  Unilife Corporation ... ASX: UNS), a developer, manufacturer and supplier of injectable ... multifaceted financing strategy that provides the Company with flexibility ... Unilife has signed an equity purchase agreement ... Fund, LLC ("LPC"), a Chicago -based ...
    (Date:7/29/2015)... , July 29, 2015  Ascendis Pharma A/S ... that applies its innovative TransCon technology to address significant ... a conference call on July 30, 2015, at 9:00 ... a Phase 2 pediatric study of once-weekly TransCon Growth ... the top-line results before the market opens on July ...
    Breaking Medicine Technology:Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 2Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 4Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 5Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time 2
    ... Kanghui Holdings (NYSE: KH ) ("Kanghui" or ... of orthopedic implants in China, today announced that all ... meeting held in Hong Kong on September 5, 2011 ... , Re-election of Mr. Yikang Jiang as a ...
    ... Discovery Labs, Inc. (Nasdaq: DSCO ) today ... Complete Response to the 2009 Complete Response Letter issued by ... (lucinactant) for the prevention of respiratory distress syndrome (RDS) ... will designate the Complete Response as a Class 2 ...
    Cached Medicine Technology:China Kanghui Holdings Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting 2Discovery Labs Submits SURFAXIN® Complete Response to FDA 2Discovery Labs Submits SURFAXIN® Complete Response to FDA 3Discovery Labs Submits SURFAXIN® Complete Response to FDA 4
    (Date:7/30/2015)... ... 2015 , ... Boston Web Marketing is proud ... Partners is the platform for search marketing agencies to communicate with the Google ... to run successful search marketing campaigns. Google Partners also affords businesses the opportunity ...
    (Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is ... a nonsurgical treatment designed specifically for the elimination of excess tissue under ... first locations in the state of Wisconsin to offer this innovative treatment. , Developed ...
    (Date:7/30/2015)... ... July 30, 2015 , ... The American Association of ... announcement of the reinstitution of National Prescription Drug Take-Back Days. The 10th event ... AM to 2:00 PM local time. On the 26th, the DEA, with the ...
    (Date:7/30/2015)... NC (PRWEB) , ... July 30, 2015 , ... New ... patients. Click here to read more on the Surviving Mesothelioma website. ... Rehabilitation Hospital in Missouri reviewed more than 12,000 cases of mesothelioma occurring between 1990 ...
    (Date:7/30/2015)... , ... July 30, 2015 , ... 1Heart Caregiver Services ... - “Learn How to Make Money in the Booming Homecare Business.” This will be ... 90010. , The event will be hosted by 1Heart’s very own ...
    Breaking Medicine News(10 mins):Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2
    ... April 18 An ex-White house aide,Robert Weiner, and ... cancer lab, are reporting that many scientists believe that ... a drop in real dollars for,cancer research, and private ... of the federal government." Discoveries are being,lost due to ...
    ... Coyote goes,hungry in cartoon land, it,s because Roadrunner ... Food Bank wins when nobody goes hungry., ... ), In that spirit, strategic communications firm ... to highlight the tragedy of hunger in New,Mexico ...
    ... showing the cancer may have an Achilles, heel, report suggests ... Gleevec has forced metastatic melanoma into remission for the first ... , The case involves a 79-year-old woman with melanoma tumors ... an abnormality in a gene called KIT, so the patient ...
    ... Family Research Council,Action applauds GOP Presidential candidate ... Villanova University supporting the pro-life,platform of the Republican ... of possible running mates., FRC Action,s Senior ... hear Senator McCain depict his support for life ...
    ... TSTF ), a national provider of healthcare and administrative,staffing ... of Shareholders held on April 17, 2008, at the ... annual meeting, shareholders approved the election of Rick J.,Filippelli ... Directors. In,addition, the Company,s shareholders also approved a proposal ...
    ... drugs had sharper declines in thinking skills, study finds ... known as anticholinergic drugs -- used to treat ulcers, ... -- may cause older people to lose their thinking ... medicines, new research suggests. , "What we found is ...
    Cached Medicine News:Health News:Reduced Funds for Cancer is Cost of Iraq, Say Ex-White House Aide, Cancer Researchers 2Health News:BEEP BEEP!! Strategic Communications Firm DW Turner Thwarts Hunger in Partnership With Roadrunner Food Bank 2Health News:Gleevec Pushes Advanced Melanoma Into Remission 2Health News:FRC Action Praises John McCain's Pro-Life Comments 2Health News:TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders 2Health News:TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders 3Health News:Common Medications May Harm Memory in Older People 2Health News:Common Medications May Harm Memory in Older People 3
    ... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
    Inquire...
    ... Aerosol barrier tips eliminate false ... Scientifically designed and tested, Promega Barrier ... working with amplified nucleic acids (PCR(a)), ... samples, forensic and serological specimens. , ...
    ... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
    Medicine Products: